Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.
Biomarker
NAFLD
NASH
PRO-C3
Steatohepatitis
fibrosis
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
02
05
2019
revised:
28
05
2019
accepted:
22
06
2019
entrez:
11
2
2020
pubmed:
11
2
2020
medline:
11
2
2020
Statut:
epublish
Résumé
There is an unmet need for non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD) that can diagnose advanced disease and identify patients suitable for clinical trials. The PRO-C3 collagen neo-epitope is a putative direct marker of fibrogenesis. We assessed the performance of PRO-C3 in a large, well-characterised international NAFLD cohort and report the development and validation of 2 novel panels for the diagnosis of advanced fibrosis (F≥3) in NAFLD, including a simplified clinical score which eliminates the need for online calculators. Plasma PRO-C3 levels were determined in a prospectively recruited international cohort of 449 patients with biopsy diagnosed NAFLD across the full disease spectrum (F0: n = 90; F1: 100; F2: 92; F3: 101; F4: 66). The cohort was divided into a discovery group (n = 151) and a validation group (n = 298). Logistic regression was performed to establish complex (FIBC3) and simplified (ABC3D) diagnostic scores that accurately identify advanced fibrosis. Performance for each was compared to established non-invasive fibrosis scoring systems. Plasma PRO-C3 levels correlated with grade of histological steatohepatitis (r Plasma PRO-C3 levels correlate with severity of steatohepatitis and fibrosis stage. The FIBC3 panel is an accurate tool with a single threshold value that maintains both sensitivity and specificity for the identification of F≥3 fibrosis in NAFLD, eliminating indeterminate results and outperforming commonly used non-invasive tools. A greatly simplified version (ABC3D) that is readily amenable to use in the clinic has been validated and shown to perform with similar accuracy, and may prove a useful tool in routine clinical practice. We performed a comprehensive, independent evaluation of a collagen biomarker (PRO-C3) to detect and quantify liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). We report the development of 2 diagnostic panels using PRO-C3 to identify patients with advanced fibrosis, one optimal but more complex to calculate (FIBC3), the other easier to use (ABC3D) whilst still performing well.
Identifiants
pubmed: 32039369
doi: 10.1016/j.jhepr.2019.06.004
pii: S2589-5559(19)30061-8
pmc: PMC7001575
doi:
Types de publication
Journal Article
Langues
eng
Pagination
188-198Informations de copyright
© 2019 The Authors.
Références
Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40
pubmed: 24768810
Hepatology. 2014 Dec;60(6):1920-8
pubmed: 25103310
Clin Gastroenterol Hepatol. 2018 Jul;16(7):1138-1145.e5
pubmed: 29452268
Biochem J. 1985 Nov 15;232(1):145-50
pubmed: 4084223
Hepatology. 1990 Nov;12(5):1106-10
pubmed: 2227807
Hepatology. 2014 Aug;60(2):565-75
pubmed: 24753132
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
J Hepatol. 2015 May;62(5):1148-55
pubmed: 25477264
Gastroenterology. 2005 Jun;128(7):1898-906
pubmed: 15940625
Hepatology. 2007 Apr;45(4):846-54
pubmed: 17393509
Hepatology. 2012 Nov;56(5):1751-9
pubmed: 22707395
J Clin Pathol. 2013 Dec;66(12):1033-45
pubmed: 23940130
Eur Radiol. 2015 Apr;25(4):932-9
pubmed: 25599932
Gastroenterology. 1988 Sep;95(3):734-9
pubmed: 3135226
Biometrics. 2005 Jun;61(2):600-9
pubmed: 16011710
Gut. 2010 Sep;59(9):1265-9
pubmed: 20801772
Radiology. 2017 May;283(2):418-428
pubmed: 27861111
J Healthc Qual. 2011 Mar-Apr;33(2):37-46
pubmed: 21385279
J Hepatol. 2014 May;60(5):1055-62
pubmed: 24445215
Sci Rep. 2018 Aug 17;8(1):12414
pubmed: 30120271
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatology. 2017 May;65(5):1557-1565
pubmed: 28130788
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Hepatology. 2018 May;67(5):1754-1767
pubmed: 28833331
J Hepatol. 2003 Aug;39(2):239-44
pubmed: 12873821
Gut. 2008 Oct;57(10):1441-7
pubmed: 18390575
Hepatology. 2011 Oct;54(4):1208-16
pubmed: 21688282
Hepatology. 2016 Jun;63(6):1817-27
pubmed: 26659452
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
Hepatology. 2010 Jun;51(6):1972-8
pubmed: 20209604
BMC Gastroenterol. 2006 Feb 14;6:6
pubmed: 16503961
Gastroenterology. 2015 Aug;149(2):389-97.e10
pubmed: 25935633
Hepatology. 2019 Mar;69(3):1075-1086
pubmed: 30014517
Hepatology. 2008 Feb;47(2):455-60
pubmed: 18038452
Am J Physiol Gastrointest Liver Physiol. 2016 Dec 1;311(6):G1009-G1017
pubmed: 27765759
Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44
pubmed: 23507799
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156
Am J Transl Res. 2013 Apr 19;5(3):303-15
pubmed: 23634241
Hepatology. 2019 Jul;70(1):127-141
pubmed: 30859582
Clin Chem. 2008 Aug;54(8):1372-8
pubmed: 18539647
Aliment Pharmacol Ther. 2013 Nov;38(9):1086-96
pubmed: 24099470
Ann Med. 2011 Dec;43(8):617-49
pubmed: 21039302
Health Technol Assess. 2007 Dec;11(50):iii, ix-51
pubmed: 18021577
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Hepatology. 2016 Jan;63(1):138-47
pubmed: 26171685
Gastroenterology. 1978 Jan;74(1):103-6
pubmed: 618417
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
Br J Gen Pract. 2002 Dec;52(485):1012-20
pubmed: 12528590
Eur J Gastroenterol Hepatol. 2013 Jun;25(6):652-8
pubmed: 23325287